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Abstract
Background: Peripheral arterial disease (PAD) is caused by narrowing of the arteries in the lower extremities.
Limited data exist concerning the impact of diffuse vascular disease (DVD) on prognosis and costs. Thus, the
objective of this study is to estimate the impact of DVD on morbidity, mortality and costs.
Methods: PAD was identified between 1985 and 1995 and classified by extent of DVD at diagnosis: none (PAD
only, reference group), prior myocardial infarction (MI), prior stroke, prior MI and stroke (MI + stroke), prior transient
ischemic attack (TIA). Deaths and hospitalizations were identified through December 2000. Hospitalization costs
were estimated from the Ontario Case Cost Project, reported in 2002 $CAD. Proportional hazards analyses
measured the impact of vascular involvement on mortality while controlling for risk factors (e.g., age, cardiovascular
history).
Results: Overall, 16,439 patients with PAD were included; 14.8% had a prior MI, 10.2% a prior stroke, 2.6% prior MI
+ stroke, 6.4% prior TIA, two-thirds had PAD only. Median survival was shorter for patients with prior MI (9.3 yrs),
TIA (6.3), stroke (4.7), and MI+stroke (4.1) versus the reference group (9.9, p < 0.05, all comparisons). Analyses
revealed that the death risk was 60% higher in patients with prior stroke and 84% higher for MI + stroke.
Atherothrombotic and bleeding event-related costs were $712, $337, $268, and $170 higher per patient/year of
follow-up in patients with a history of MI+stroke, MI, stroke, and TIA, respectively.
Conclusion: Patients diagnosed with PAD with DVD have higher risk of poor outcomes and increased costs.
Background
Cardiovascular disease (CVD) risk has been studied
mainly in relation to a patient’s most recent event. Most
secondary prevention clinical trials enroll patients at an
arbitrary point in their disease. In CAPRIE, randomiza-
tion was according to the most recent manifestation of
CVD, yet fully understanding a new therapy’s impact
requires understanding the impact of involvement in
multiple vascular beds on subsequent risk. Peripheral
arterial disease (PAD) is a condition caused by progres-
sive narrowing of the arteries in the lower extremities
[1] often leading to serious cardiovascular complications
and, sometimes, death [2-6]. Studies conducted in the
United States and Europe have shown that the preva-
lence of PAD ranges from <5% in younger age groups
to >20% in the elderly [7-9]. In Canada, the prevalence
of PAD is estimated around 4% in people ≥40 years of
age [1].
Some evidence indicates that PAD negatively impacts
the prognosis of patients with diffuse vascular disease
(DVD). Studies have demonstrated that history of PAD
is associated with more extensive coronary artery disease
(CAD) and higher death rates [3,10] in patients suffering
a coronary artery event. Moreover, evidence shows that
this subgroup is often under-diagnosed and frequently
undertreated; only 25% of patients diagnosed with PAD
receive treatment despite having an increased risk for
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impact of diffuse vascular involvement (>1 vascular bed)
on outcomes and survival following a diagnosis of PAD
are available. This study examines the relationship using
data from Saskatchewan Health.
Methods
Data Source & Patient Population
Data for this study were obtained from Saskatchewan
Health, an agency responsible for healthcare administra-
tion in the Canadian province of Saskatchewan. Sas-
katchewan Health maintains 10 databases tracking all
formulary outpatient prescriptions, physician services,
hospitalizations, and vital statistics for the approximately
1 million residents covered by provincial health insur-
ance [12].
Residents of Saskatchewan ≥21 years of age with a
diagnosis of PAD between January 1, 1985 and Decem-
ber 31, 1995 were selected for inclusion. We identified
patients with PAD using the International Classification
of Diseases, 9
th Revision (ICD-9) diagnosis codes 440.x
(atherosclerosis), 440.2 (atherosclerosis of native arteries
of the extremities), and 443.9 (peripheral vascular dis-
ease (PVD)). Only the truncated three-digit code was
available for diagnoses made on physician visit, thus
patients with the broader three-digit code 443 (other
PVD) were included if they received a prescription for
pentoxifylline at any point in time as this was consid-
ered a conclusive clinical indicator of PAD. No exclu-
sion criteria were specified. The date of the first PAD
diagnosis on either a hospital or physician services
record was taken as the study index date.
Patients were classified into one of five subgroups
according to of the extent of DVD involvement at index
diagnosis: (1) no history of DVD (PAD only); (2) history
of myocardial infarction (MI) only (MI); (3) history
of stroke only (stroke); (4) history of MI and stroke
(MI+stroke); and (5) history of transient ischemic attack
(TIA) only (TIA). This was ascertained using ICD-9
diagnosis codes from hospital and physician services
records (ischemic stroke: 433.x, 434.x; TIA: 435.9, 436.x;
MI/unstable angina: 410.x, 412.x). Medical histories
were available back to January 1, 1980. Histories were
also examined to identify other comorbid conditions
including atrial fibrillation, angina, heart failure,
hypercholesterolemia, hypertension, and diabetes. The
location (hospital or physician visit) where the index
PAD diagnosis occurred was also recorded.
Hospitalizations Related to Atherothrombotic Disease
Morbidity was assessed by examining the hospitaliza-
tions for 1) any cause and 2) those related to major
atherothrombotic and bleeding events (ABE). ABE-
related hospitalizations were classified using primary
ICD-9 diagnosis codes appearing on hospital records.
Hospitalizations were considered ABE-related if they
were coded with a diagnosis code indicating ischemic
stroke (433.x, 434.x), TIA (436.x, 435.9), MI (410.x,
412.x), angina (411.x, 413.x), heart failure (428.x), PAD
(440.x, 443.x), or bleeding (430.x, 431.x, 432.x, 459.x,
578.x). The time to first hospitalization (any cause or
ABE-related) was calculated in years from the study
index date until the first hospitalization event. The time
in years from the first to second study hospitalization
(any cause or ABE-related) was also assessed.
Hospitalization Costs Related to Atherothrombotic
Disease
Hospital cost data were not obtained from Saskatchewan
Health for this study. Thus, costs related to ABE events
were acquired from an external source–the 2000
Ontario Case Cost Project (OCCP) Case Mix Group
Costing Analysis Tool (CAT) [13]. This same approach
was utilized in a prior analysis of the Saskatchewan data
[14]. Studies estimating PAD costs have shown that 75%
of total costs are driven by hospitalizations [15]. A list-
ing of the cost estimates used for specific types of ABE-
related hospitalizations is s h o w ni nT a b l e1 .H o s p i t a l
costs are standardized to 2002 $CAD and presented as
per-patient means.
Study Follow-up
Study outcomes including survival, morbidity, and hos-
pital costs were evaluated from the index PAD diagnosis
and ending at the earlier of the date of death, study con-
clusion (December 31, 2000), or end of follow-up in the
Saskatchewan data.
Data Analyses
Baseline demographic and clinical characteristics includ-
ing age, gender, index location (i.e., hospital or physician
record), and medical history were compared across sub-
groups. Group comparisons were made using two-sided
Pearson chi square and t-test statistics for categorical
and continuous measures, respectively.
Life expectancy for each vascular involvement sub-
group was estimated using Kaplan-Meier survival analysis
techniques. Patient time was calculated as the number of
months from the index PAD diagnosis until either the
date of death or censoring. Patients were censored if they
were still alive as of their last day of available follow-up
in the data set. Overall survival was compared using the
log-rank test. Proportional hazards models were created
to measure the impact of DVD history on mortality while
controlling for competing risk factors including age, gen-
der, and past histories of atrial fibrillation, angina, heart
failure, and hypertension. Interaction terms for history of
TIA and time, history of MI+stroke and time, history of
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Hospitalization type Costs (2002 $CAD)
Cerebrovascular
Ischemic stroke $7,793
TIA with no related procedures $2,687
TIA with carotid endarterectomy $4,689
Cardiovascular
AMI with no surgical procedures
AMI, unspecified cardiac condition $3,805
AMI with CHF $7,064
AMI with angina $4,564
AMI with cardiogenic shock and/or PE $16,252
AMI with surgical procedures
AMI with CABG and CC $18,564
AMI with CABG $12,004
AMI with PCTA $8,189
AMI with CC/angiography $6,161
AMI with CHF and CC/angiography $9,349
AMI with angina and CC/angiography $6,661
AMI with permanent pacemaker $7,379
Angina
Angina as primary diagnosis $2,352
UA with cardiac complication $3,227
UA without cardiac complication $2,144
UA with cardiogenic shock and/or PE $16,253
Angina with surgical procedures
UA or angina with CABG and CC $18,564
UA or angina with CABG $12,004
Angina w/o cardiac complication with PTCA or stent $4,748
Angina with cardiac complication with PTCA or stent $8,189
UA with CC/coronary angio $5,803
UA with cardiac complications and CC/coronary angio $8,774
Angina with CC/coronary angio $3,740
Other cardiac problems
CHF $4,074
CHF with CC $4,916
Arrhythmia/Conduction disorders no pacemaker $2,159
Arrhythmia/Conduction disorders with permanent pacemaker $7,379
Peripheral Vascular Disease
PAD, no major vascular surgery $4,273
PAD with aorto-iliac-femoral bypass graft $11,403
PAD with intra-abdominal bypass graft $11,403
PAD with other peripheral bypass graft $4,017
PAD with lower limb Embolectomy $4,017
PAD with upper limb or toe amputation $9,239
PAD with foot amputation $12,519
PAD with below the knee amputation $12,344
PAD with above the knee amputation $12,420
Major bleeds
ICH, no surgical procedures $12,134
GI bleed, no surgical procedures $2,826
Hemorrhage, unspecified with no surgical procedures $6,218
GI bleed with gastrectomy/other major gastric surgery $11,050
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included because the proportionality of the effect of these
determinants could not be verified.
T h em e a nt i m et ot h ef i r s th o s p i t a l i z a t i o na n dm e a n
time from the first to the second hospitalization was
determined for any cause and ABE-related hospitaliza-
tions. Only patients who experienced a hospitalization
contributed to the mean time calculations, therefore,
comparisons between the groups were made using the
t-test statistic. The proportion of patients hospitalized
for specific ABE-related events (Stroke/TIA, MI/Angina,
and Other CVD) were compared across subgroups.
Group comparisons were made using the two-sided
Pearson chi square test.
Cost data were analyzed using descriptive statistics
(i.e., means and standard deviations). Non-parametric
bootstrap methods were used to calculate the 95% confi-
dence intervals around the per-patient cost estimates
[16]. First, the data were re-sampled with replacement
from the study dataset to create 1,000 random samples.
Next, inpatient ABE-related costs were calculated for
each of the 1,000 study replicates. Finally, confidence
intervals were derived from the sample distribution of
costs of the 1,000 replicates at the 2.5% and 97.5% quan-
tiles. Costs were also calculated per study year to adjust
for differences in the length of follow-up observed
between study groups. Statistical significance was evalu-
ated at an alpha = 0.05 for all tests. Unless otherwise
specified, a t-test was performed using the PAD only
subgroup as the reference category.
Results
Patient Characteristics
Additional file 1: Table S1 displays baseline characteris-
tics by vascular disease subgroup. A cohort of 16,439
patients diagnosed with PAD was identified including
2,437 (14.8%) with a prior MI, 1,679 (10.2%) with prior
stroke, 431 (2.6%) with prior MI + stroke, and 1,048
(6.4%) with prior TIA. Patients across any of the sub-
groups containing stroke/TIA were almost 4 years older
than those with PAD only (70.3 vs. 66.7 years,
p < 0.001) and MI only (70.3 vs. 65.6 years, p < 0.001).
Patients with DVD were more likely to have ABE-
related comorbidities (90% vs. 73%, p < 0.001). Length
of follow-up was on average one year shorter in patients
with a history of DVD (6.4 vs. 7.4 years, p < 0.001).
Mortality & Morbidity
Patients with a history of DVD were more likely to die
during the study period (Additional file 1: Table S1;
67.6% vs. 52.3%, p < 0.001). Median survival (in years)
was progressively worse for patients with a history of MI
(9.3 years), TIA (6.3), stroke (4.7), and MI+stroke (4.1)
compared to the PAD only subgroup (9.9) (Figure 1,
p < 0.05, all comparisons). Table 2 displays results of pro-
portional hazards models examining the risk of death,
subsequent MI, and subsequent ischemic stroke. After
controlling for competing risk factors, a 60% and 84%
increase in the hazard of death in patients with a history
of stroke (p < 0.001) and MI+stroke (p < 0.001), respec-
tively, was observed. Diffuse involvement including a
stroke or MI+stroke was also associated with higher rates
of MI (Stroke: p < 0.05, MI+stroke: p < 0.001) and
ischemic stroke (Stroke: p < 0.001, MI+stroke: p < 0.001).
Those with a history of TIA were 61% more likely to
have an ischemic stroke (p < 0. 001).
Hospitalizations Related to Atherothrombotic Disease
A higher proportion of patients with DVD were hospita-
lized for ABE-related events versus PAD only (Figure 2;
48.6% vs. 34.2%, p < 0.001). The rate of hospitalization
for ABE events increased according to the type and
extent of DVD (Figure 2, TIA: 40.5%, Stroke: 42.8%, MI:
54.5%, and MI + Stroke: 56.4%). Patients with a history
of MI were more likely to be hospitalized for an MI/
angina event compared to those with PAD only (33.8%
vs. 14.1%, p < 0.001) or those with a history of stroke or
TIA (33.8% vs. 14.8%, p < 0.001). Patients with a medi-
cal history of stroke or TIA were also more susceptible
to having a stroke or TIA event requiring hospitalization
compared to patients without such a history (22.0% vs.
10.8%, p < 0.001).
Table 1 OCCP Case Mix Group cost estimates (Continued)
GI bleed with endoscopy $4,017
AMI = acute myocardial infarction
CABG = coronary artery bypass graft
CC = cardiac catheterization
CHF = congestive heart failure
GI = gastrointestinal
ICH = intracranial hemorrhage
PAD = peripheral arterial disease
PE = pulmonary embolus
PTCA = percutaneous transluminal coronary angioplasty
TIA = transient ischemic attack
UA = unstable angina
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was almost one year shorter for patients with DVD com-
pared to PAD only (Additional file 2: Table S2, 4.4 vs. 5.3
years, p < 0.001). Although patients with a history of DVD
were hospitalized for any cause at similar rates compared to
PAD only (86%), the average time to this hospitalization was
6 months shorter for patients with DVD as compared to
those with PAD only (Additional file 2: Table S2, 1.7 vs. 2.3
years, p < 0.001). Patients with a history of DVD were also
more likely to suffer a repeat ABE-related hospitalization
compared with PAD only patients (25.8% vs. 15.6%, p <
0.001). Amongst patients who suffered a second event, how-
ever, the length of time from the first to second ABE-related
hospitalization in patients with a history of DVD compared
with those diagnosed with PAD only was not as disparate as
the time to the first ABE-related hospitalization (DVD: 1.7
vs. PAD only: 1.9 years, p = 0.02). The proportion of patients
with a second hospitalization from any cause was compar-
able in those with DVD (72.2%) and PAD only (69.3%, p <
0.01). Patients with a history of DVD had a second hospitali-
zation from any cause that occurred on average 3.6 months
earlier versus PAD only (1.3 vs. 1.6 years, p < 0.001).
Hospitalization Costs Related to Atherothrombotic
Disease
The patient subgroups with a history of DVD had
higher mean per-patient ABE-related hospital costs
(DVD: $4 718, 95% CI: $3 391-$6 611, p < 0.0001 vs.
PAD only; MI: $5 355, 95% CI: $5 088-$6 753, p <
0.0001; Stroke: $4 088, 95% CI: $3 774-$4 400, p <
0.0001; MI+Stroke: $6 097, 95% CI: $5 372-$6 884, p <
0.0001; TIA: $3 677, 95% CI: $3 248-$4 159, p < 0.002)
in comparison to PAD only ($2 979, 95% CI: $2 854-$3
102) (Figure 3). Inpatient ABE-related per-patient costs
were $757, $348, $331, and $193 higher per year of fol-
low-up versus PAD only in patients with a history of
MI+stroke, stroke, MI, and TIA, respectively (Figure 3).
Discussion
This study presents, to the best of our knowledge, a novel
evaluation of the impact of DVD involvement on
Figure 1 Kaplan-Meier survival following diagnosis of PAD by type of diffuse vascular disease history
Table 2 Hazard ratios of death, MI and ischemic stroke
by risk factors
Study Measure Death MI Ischemic stroke
Age at index diagnosis 1.08
† 1.02
† 1.05
†
Male gender 1.28
† 1.69
† 1.32
†
History of:
MI 1.06** 1.66
† 1.17*
Stroke 1.60
† 1.29* 3.11
†
MI+stroke 1.84
† 1.76
† 3.26
†
Atrial fibrillation 1.17** – 1.64
†
Angina 0.84
† 1.44
† –
Heart failure 1.89
† – 1.18*
Hypercholesterolemia 0.77
† ––
Hypertension – 1.21** 1.52
†
Diabetes 1.37
† 1.49
† –
TIA 1.04 – 1.61
†
Interaction terms
TIA × follow-up 1.02* ––
MIx follow-up –– –
Stroke × follow-up –– 0.95*
MI + stroke × follow-up 0.96* – 0.93*
Final models are presented; factors that were not statistically significant were
excluded since they can introduce noise and reduce precision of estimates
MI = myocardial infarction
TIA = transient ischemic attack
*p < 0.05
**p < 0.01
† p < 0.001
– = not statistically significant
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Figure 3 Mean costs of hospitalizations related to cardiovascular events (CV), by type of diffuse vascular history
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Saskatchewan Health databases were used to examine the
impact of varying degrees of involvement on survival, hos-
pitalizations, and costs following a diagnosis of PAD.
Previous studies have focused on the link between a
prior PAD diagnosis and higher mortality in patients
with CAD [3,10,17]. These results can be compared to
those reported in these prior studies to understand the
difference in impact that a prior diagnosis of PAD has
on mortality in CAD versus the impact that a prior
DVD diagnosis has on patients with PAD. Cotter et al.
found that, after adjustment for risk factors, a history of
cerebrovascular accidents, TIA, or PAD in patients with
acute coronary syndromes is significantly associated
with a 47% increase in the risk of mortality [10]. A
study investigating the long-term impact of PAD on
outcomes in patients with acute MI (AMI) found that
the risk of death was 29% higher in patients with prior
PAD [17]. Froehlich and colleagues found that a prior
diagnosis of PAD increases the risk of mortality by
nearly 19% in patients with acute coronary syndromes
[3]. In the current study, history of stroke or MI+stroke
had a greater impact on mortality in patients with PAD
compared to the reported impact of prior PAD in
patients with CAD [3]. It could be posited that the
occurrence of an acute event prior to, rather than fol-
lowing, diagnosis of PAD is an indicator of more severe
disease. Prior MI in patients with PAD had little added
impact on mortality whereas the impact of prior PAD in
patients with AMI has been shown to be significant [17].
That patients with PAD continue to be under-diag-
nosed and under-managed despite the pervasive evi-
dence that they are at increased risk for poor outcomes
[3,9-11] is astounding. Our analyses further contribute
to this knowledge base indicating that patients with
PAD are at considerable risk for morbidity, mortality,
and incurring substantial costs associated with these.
Moreover, when there is a history of DVD these patients
face an even higher burden in terms of subsequent
events and costs. Limited data examining the impact of
diffuse vascular involvement (>1 vascular bed) on out-
comes and survival following a diagnosis of PAD are
available.
This study was subject to several limitations. In identi-
fying the PAD population, study subgroups, and ABE-
related hospitalizations, we relied on ICD-9 diagnosis
codes submitted by health-care providers to the pro-
vince of Saskatchewan. These codes are primarily used
for administrative purposes in obtaining reimbursement
for the services provided to Saskatchewan residents,
thus research is not the primary purpose of these data.
Therefore, there is the possibility that some PAD
patients and ABE-related hospitalizations were misclassi-
fied. Past validation studies examining the accuracy of
the administrative codes contained within the Saskatche-
wan data, however, have revealed low error rates [12].
In our analysis of costs, only measures related to ABE
hospitalizations were considered thus not accounting for
the additional costs associated with outpatient manage-
ment and medication use. However, prior studies exam-
ining PAD have shown that 75% of total costs are
driven by hospitalizations [15]. Therefore, we believe
that while this approach may underestimate the absolute
values, it nevertheless provides a reasonable estimate of
the relative economic burden of PAD. Hospital costs
were estimated from the province of Ontario using the
1999/2000 OCCP Case Mix Group CAT, a source exter-
nal to the Saskatchewan data. Hospitalization data could
not be obtained with consistent reliability from Sas-
katchewan at the time of this study and therefore it is
not clear the extent to which the Ontario rates reflect
the reimbursement rates provided to hospitals from
Saskatchewan.
Conclusion
This study indicates that patients with DVD involve-
ment have significantly poorer prognoses and higher
c o s t sa n dr e s o u r c eu s ea sc o m p a r e dt op a t i e n t sd i a g -
nosed only with PAD. A history of DVD amongst these
patients, particularly MI+stroke, increased the risk of
morbidity and mortality and the corresponding costs.
Appropriate management of patients with PAD is an
important public health issue as this condition affects a
large number of Canadians with involvement of DVD
being present in one-third of our actual practice popula-
tion. Amongst the Canadian population in the REACH
Registry, over 60% of the PAD patients have DVD [18].
When compared to the Saskatchewan database, a
broader range of patients were enrolled in the REACH
Registry. Thus, PAD identified and treated early, before
vascular involvement becomes diffuse, provides the
opportunity to significantly reduce morbidity and mor-
tality amongst this patient group. Moreover, it is critical
to understand the full extent of vascular disease involve-
ment when determining the prognosis and management
of patients who present with PAD.
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